PTGS1
Prostaglandin G/H synthase 1
As of the edition of 20 October 2026, PTGS1 (prostaglandin G/H synthase 1, UniProt P23219) has 60 drugs tested at it and 90 companies on the list, 4 on route A and 21 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P23219
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 1
- Disease areas
- Heart and blood vessels; Nervous system; Cancer; Bones, joints and muscles; Digestive system; Urinary and reproductive; Pregnancy and women's health; Immune system
- Registered trials of its drugs
- 3,000
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 42 |
| Went quiet | 6 |
| Stopped | 1 |
| Withdrawn from market | 9 |
| Status not established | 2 |
| Total | 60 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Acetaminophen | Marketed | Phase 4 | none listed |
| Aspirin | Marketed | Phase 4 | none listed |
| Ibuprofen | Marketed | Phase 4 | none listed |
| Ketorolac | Marketed | Phase 4 | none listed |
| Diclofenac | Marketed | Phase 4 | none listed |
| Naproxen | Marketed | Phase 4 | none listed |
| Indomethacin | Marketed | Phase 4 | none listed |
| Mesalamine | Marketed | Phase 4 | Ends 2027 |
| Ketoprofen | Marketed | Phase 4 | none listed |
| Flurbiprofen | Marketed | Phase 4 | none listed |
| Sulfasalazine | Marketed | Phase 4 | none listed |
| Metamizole | Marketed | Phase 4 | none listed |
12 of 60 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 4 |
| Route B | 21 |
| Engaged | 38 |
| Undetermined | 27 |
| Total on the list | 90 |
The other 87 companies at PTGS1
In the product90 companies in all; 87 are not named here, and no score is.
See the 90 companies at PTGS1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.